

Evidences for the Involvement of Monoaminergic and GABAergic Systems in Antidepressant-like Activity of *Tinospora cordifolia* in Mice

D. DHINGRA* AND P. K. GOYAL

Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar-125001, India.

Dhingra, *et al.*: *Tinospora cordifolia*: An effective antidepressant

The present study was taken up to investigate the effect of petroleum ether extract of *Tinospora cordifolia* (Wild.) Miers, on depression in mice. The extract (50, 100 and 200 mg/kg, p.o.) was administered for 14 successive days to Swiss young albino mice (either sex) and evaluated for antidepressant-like activity using tail suspension test and forced swim test. Petroleum ether extract at all three doses produced significant antidepressant-like effect in tail suspension test as well as in forced swim test and their efficacies were found to be comparable to imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.). The extract at a dose of 50 mg/kg showed most potent effect and did not show any significant change in locomotor functions of mice as compared to control. The antidepressant-like effect of the extract was significantly reversed by pretreatment of animals with prazosin (a α_1 -adrenoceptor antagonist), sulpiride (a selective dopamine D_2 -receptor antagonist), p-CPA (a serotonin synthesis inhibitor) and baclofen (GABA-B agonist), when tested in tail suspension test. Moreover, petroleum ether extract also reduced the mouse whole brain monoamine oxidase (MAO-A and MAO-B) activities as compared to control, resulting in increase in the levels of brain monoamines. Therefore, the extract may have potential therapeutic value for the management of depressive disorders.

Key words: Depression, forced swim test, monoamine oxidase, tail suspension test, *Tinospora cordifolia*

Mental depression represents a major public health problem worldwide. The high prevalence of suicide in depressed patients (up to 15%) coupled with complications arising from stress and its effects on the cardiovascular system have suggested that it will be the second leading cause of death by the year 2020¹. The use of alternative medicines is increasing worldwide day by day. *Hypericum perforatum*, a well known plant has been proven to be effective antidepressant in clinical studies². Thus, there is a constant need to identify newer natural antidepressants with greater efficacy, and to explore their potential over synthetic antidepressants. *Tinospora cordifolia* (Family: Menispermaceae), a well known plant of Indian medicinal system, was selected for evaluating antidepressant-like activity in laboratory animals, since this plant has been reported to possess antistress activity^{3,4}. According to the Ayurvedic System of Medicine, *T. cordifolia* is an antigout, analgesic,

rejuvenator, astringent, anthelmintic, antiarthritic, antiperiodic, antipyretic, antimalarial, antiinflammatory, aphrodisiac, antiasthmatic, bitter tonic, carminative, cardiogenic, constipative, digestant, diuretic, blood purifier, expectorant, antidiabetic, antigonorrhoeal, cholagogue, antiemetic and antiicteric⁵⁻⁷. *T. cordifolia* has been claimed to possess learning and memory enhancing⁸, antioxidant⁹, antiischemic¹⁰, hypolipidaemic¹¹, antidiabetic¹², antiulcer¹³, hepatoprotective¹⁴, antifertility¹⁵, antiinflammatory¹⁶, antiallergic¹⁷, immunomodulatory¹⁸, anticancer¹⁹ and radioprotective²⁰. The chemical constituents of *T. cordifolia* stems include alkaloids like berberine, palmatine, tembetarine, magnoflorine^{21,22}, glycosides like tinocordiside²³, tinocordifolioside, cordioside²⁴, cordifolioside A, B²⁵, cordifolioside A, B, C, D, E^{26,27}, steroids like ecdysterone, makisterone A, giloinsterol²⁸, sesquiterpenoids like tinocordifolin²⁹. Thus, the aim of the present study was to explore the antidepressant potential of *T. cordifolia* and to investigate the probable underlying mechanisms of action.

*For correspondence

E-mail: din_dhingra@rediffmail.com

MATERIALS AND METHODS

Swiss mice of either sex, weighing around 20-25 g were purchased from Disease-free Small Animal House, Chaudhary Charan Singh Haryana Agricultural University, Hisar (Haryana, India). Male and female animals were housed separately in groups of 6 per cage (polycarbonate cage size: 29×22×14 cm) under laboratory conditions with alternating light and dark cycle of 12 h each. The animals had free access to food and water. The animals were kept fasted 2 h before and 2 h after drug administration. The animals were acclimatized for at least five days before behavioral experiments which were carried out between 09:00 and 17:00 h. The experimental protocol was approved by Institutional Animals Ethics Committee (IAEC) and animal care was taken as per the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Govt. of India (Registration No. 0436).

Sertraline hydrochloride (Aurobindo Pharma Ltd., Hyderabad, India), prazosin hydrochloride, (\pm) sulpiride, DL para-chlorophenylalanine, baclofen and imipramine hydrochloride (Sigma-Aldrich, St. Louis, USA); Tween 80 (Loba Chemie, Mumbai, India); petroleum ether (60-80°), Tris (hydroxymethyl) aminomethane, benzylamine (S. D. Fine-Chem Ltd., Mumbai, India), di-sodium hydrogen phosphate (Merck Ltd, Mumbai, India), sodium di-hydrogen orthophosphate, sucrose, acetic acid, hydrochloric acid (Qualigens Fine Chemicals, Mumbai, India), EDTA di-sodium salt, sodium hydroxide pellets, 5-hydroxy tryptamine, creatine sulphate (Hi-Media Laboratories Pvt. Ltd., Mumbai, India), bovine serum albumin (Spectrochem Pvt. Ltd., Mumbai, India) were used in the present study.

Collection of plant material:

The dried stems of *T. cordifolia* were purchased from the commercial market, New Delhi and were authenticated as *Tinospora cordifolia* (Wild.) Miers ex Hook. f. and Thoms from Raw Materials Herbarium and Museum section of National Institute of Science Communication and Information Resources, New Delhi (Ref. No. NISCAIR/RHMD/Consult/06/741/58).

Preparation of petroleum ether extract:

The dried stems were grounded to coarse powder. About 1kg of powdered drug was extracted with petroleum ether (60-80°) using Soxhlet apparatus at

70° till siphoning solution became colorless. The solvent was recovered by distillation and the extract was dried by using water bath at 50-60°. The dried petroleum ether extract was yellowish in color and the yield was 0.89%. The dried extract was stored in air tight container and kept in a refrigerator.

Preliminary phytochemical screening:

For preliminary phytochemical screening, petroleum ether extract was tested for the presence of alkaloids, glycosides, carbohydrates, sterols, phenolic compounds and tannins, flavonoids, saponins, proteins and amino acids following the standard procedures³⁰. The extract of *T. cordifolia* was emulsified in 10% v/v Tween 80. Imipramine, sertraline, prazosin and baclofen were separately dissolved in normal saline (0.9% NaCl). Sulpiride was dissolved in normal saline followed by the addition of one drop of glacial acetic acid. p-CPA was dissolved in minimum quantity of 0.1N sodium hydroxide solution and pH was adjusted to 7.0 with 0.1N hydrochloric acid³¹.

Tail suspension test (TST):

TST, commonly employed behavioral model for screening antidepressant-like activity in mice, was first discovered by Steru *et al.*³². The test was conducted as previously followed³¹. Animals were moved from their housing colony to laboratory in their own cages and allowed to adapt to the laboratory conditions for 1-2 h. Each mouse was individually suspended to the edge of a table, 50 cm above the floor, by adhesive tape placed approximately 1 cm from the tip of the tail. Each animal under test was both acoustically and visually isolated from other animals during test. The total period of immobility was recorded manually for 6 min. Animal was considered to be immobile when it didn't show any body movement, hung passively and completely motionless. The test was conducted in a dim lighted room and each mouse was used only once in the test. The observer, recording the immobility of animals, was blind to the drug treatments given to the animals under study.

Forced swimming test (FST):

FST, the most frequently used behavioral model for screening antidepressant-like activity in rodents, was first proposed by Porsolt *et al.*³³. The procedure was same as previously followed³¹. Animals were moved from their housing colony to laboratory in their own cages and allowed to adapt to the laboratory conditions for 1-2 h. Mice were individually forced to swim in

open glass chamber (25×15×25 cm³) containing fresh water to a height of 15 cm and maintained at 26±1°. Water in the chamber was changed after subjecting each animal to FST because used-water has been shown to alter the behavior³⁴. Each animal showed vigorous movement during initial 2 min period of the test. The duration of immobility was manually recorded during the next 4 min of the total 6 min testing period. Mice were considered to be immobile when they ceased struggling and remained floating motionless in water, making only those movements necessary to keep their head above water. The test was conducted in a dim lighted room and each mouse was used only once in the test³⁵. The observer, recording the immobility of animals, was blind to the drug treatments given to the animals under study.

Measurement of MAO-A and MAO-B:

On 14th day, mice were sacrificed after 6 min exposure to FST, and the brain samples were collected immediately on a ice plate. The collected brain samples were washed with cold 0.25M Sucrose, 0.1M Tris, 0.02M EDTA buffer (pH 7.4) and weighed. The whole procedure of brain isolation was completed within five minutes³⁶⁻³⁷. Mouse brain mitochondrial fractions were prepared following the procedure of Schurr and Livne³⁶. The MAO activity was assessed spectrophotometrically³⁷⁻³⁹. Briefly, the buffer washed brain sample was homogenized in 9 volumes of cold 0.25 M sucrose, 0.1 M Tris, 0.02 M EDTA buffer (pH 7.4) buffer and centrifuged twice at 800 g for 10 min at 4° in cooling centrifuge (Remi instruments, Mumbai). The pellet was discarded. The supernatant was then centrifuged at 12000 g for 20 min at 4° in cooling centrifuge. The precipitates were washed twice with about 100 ml of sucrose-Tris-EDTA buffer and suspended in 9 volumes of cold sodium phosphate buffer (10 mM, pH 7.4, containing 320 mM sucrose) and mingled well at 4° for 20 min. The mixture was then centrifuged at 15000 g for 30 min at 0° and the pellets were re-suspended in cold sodium phosphate buffer. The protein concentration was estimated by Lowry method using bovine serum albumin as the standard⁴⁰. The assay mixture contained 100 µl of 4 mM 5-hydroxytryptamine and 100 µl of 0.1 M benzylamine as the specific substrate for MAO-A and MAO-B, respectively, 150 µl solution of mitochondrial fraction and 2.75 ml sodium phosphate buffer (100 mM, pH 7.4).

For estimating MAO-B activity, 2.75 ml sodium

phosphate buffer (100 mM, pH 7.4) and 100 µl of 0.1 M benzylamine were mixed in a quartz cuvette which was then placed in double beam spectrophotometer (Systronics 2203, Bangalore, India). This was followed by the addition of 150 µl solution of mitochondrial fraction to initiate the enzymatic reaction and the change in absorbance was recorded at wavelength of 249.5 nm for 5 min against the blank containing sodium phosphate buffer and benzylamine.

For estimating MAO-A activity, 2.75 ml sodium phosphate buffer (100 mM, pH 7.4) and 100 µl of 4 mM 5-hydroxytryptamine were mixed in a quartz cuvette which was then placed in double beam spectrophotometer (Systronics 2203, Bangalore, India). This was followed by the addition of 150 µl solution of mitochondrial fraction to initiate the enzymatic reaction and the change in absorbance was recorded at wavelength of 280 nm for 5 min against the blank containing sodium phosphate buffer and 5-hydroxytryptamine.

Measurement of locomotor activity:

To rule out the effects of the extract on immobility period, horizontal locomotor activities of control and test animals were recorded for a period of 10 min using Medcraft Photoactometer- Model No. 600-4D (INCO, Ambala, India).

Animals were divided into 25 groups and each group comprised of a minimum of 6 mice. The experimental protocol was divided into the following parts:

Antidepressant-like activity using tail suspension test:

In group 1 (control group), 10% v/v Tween 80 was administered orally for 14 consecutive days and on 14th day, 60 min after the administration; immobility period was recorded in TST. In groups 2 and 3, imipramine (15 mg/kg) and sertraline (20 mg/kg) respectively were orally administered for 14 successive days and on 14th day, 60 min after the administration; immobility period was recorded in TST. In groups 4, 5 and 6, petroleum ether extract (50, 100 and 200 mg/kg, p.o. respectively) of *T. cordifolia* was administered for 14 successive days and on 14th day, 60 min after the administration, immobility period was recorded in TST.

Antidepressant-like activity using forced swim test:

Group 7 to 12 were similar as mentioned under TST

(Group 1 to 6) except that the immobility period was recorded using FST. Thus, group 7 was similar to group 1; group 8 was similar to group 2 and so on.

Mechanisms of action studies in tail suspension test:

In group 13 (sulpiride control), vehicle (10% v/v Tween 80) was administered orally for 14 consecutive days and on 14th day, after 45 min of vehicle treatment; sulpiride (50 mg/kg, i.p.) was injected. After 45 min of injection, the animals were subjected to tail suspension test. In group 14, petroleum ether extract (50 mg/kg, p.o.) of *T. cordifolia* was administered for 14 consecutive days and on 14th day, after 45 min of extract treatment; sulpiride (50 mg/kg, i.p.) was injected and the animals were subjected to tail suspension test after 45 min of the injection. In group 15 (baclofen control), vehicle (10% v/v Tween 80) was administered orally for 14 consecutive days and on 14th day, after 45 min of vehicle treatment; baclofen (10 mg/kg, i.p.) was injected. After 45 min of injection, the animals were subjected to tail suspension test. In group 16, petroleum ether extract (50 mg/kg, p.o.) of *T. cordifolia* was administered for 14 consecutive days and on 14th day, after 45 min of extract treatment; baclofen (10 mg/kg, i.p.) was injected and the animals were subjected to tail suspension test after 45 min of the injection. In group 17 (prazosin control), vehicle (10% v/v Tween 80) was administered orally for 14 consecutive days and on 14th day, after 45 min of vehicle treatment; prazosin (62.5 µg/kg, i.p.) was injected. After 45 min of injection, the animals were subjected to tail suspension test. In group 18, petroleum ether extract (50 mg/kg, p.o.) of *T. cordifolia* was administered for 14 consecutive days and on 14th day, after 45 min of extract treatment; prazosin (62.5 µg/kg, i.p.) was injected and the animals were subjected to tail suspension test after 45 min of the injection. In group 19 (p-CPA control), vehicle (10% v/v Tween 80) was administered orally for 14 consecutive days. pCPA (100 mg/kg, i.p.) was injected from 11th to 14th day after 45 min of vehicle treatment. On 14th day, the animals were subjected to tail suspension test after 45 min of pCPA injection. In group 20, petroleum ether extract (50 mg/kg, p.o.) of *T. cordifolia* was administered for 14 consecutive days. pCPA (100 mg/kg, i.p.) was injected from 11th to 14th day after 45 min of vehicle treatment. On 14th day, the animals were subjected to tail suspension test after 45 min of pCPA injection.

Estimation of brain MAO:

In group 21, vehicle (10% v/v Tween 80) was administered orally for 14 successive days and on 14th day, 60 min after the administration; the animals were subjected to forced swim test for 6 min, and immediately brain samples were collected. MAO-A and MAO-B levels were measured in the brain samples. In group 22, imipramine (15 mg/kg, p.o.) was administered orally for 14 successive days and on 14th day, 60 min after the administration; the animals were subjected to forced swim test for 6 min, and immediately brain samples were collected. MAO-A and MAO-B levels were measured in the brain samples. In group 23, petroleum ether extract (50 mg/kg, p.o.) was administered orally for 14 successive days and on 14th day, 60 min after the administration; the animals were subjected to forced swim test for 6 min, and immediately brain samples were collected. MAO-A and MAO-B levels were measured in the brain samples.

Measurement of locomotor activity:

In group 24, vehicle (10% v/v Tween 80) was administered orally for 14 successive days and on 14th day, 60 min after the administration; locomotor activity was measured. In group 25, petroleum ether extract (50 mg/kg, p.o.) of *T. cordifolia* were administered for 14 consecutive days and on 14th day, 60 min after the administration; locomotor activity was measured.

Statistical analysis:

All the results were expressed as mean±standard error mean (SEM). The data of all the groups were analyzed using one-way ANOVA followed by Dunnett's t-test using the software Sigma-Stat 3.5. The data for locomotor activity scores was subjected to Student's unpaired t-test. In all the tests, the criterion for statistical significance was $P < 0.05$.

RESULTS

The results of phytochemical screening indicated the presence of alkaloids, glycosides, carbohydrates, sterols and flavonoids in petroleum ether extract.

Effect of petroleum ether extract on immobility periods in TST and FST:

Petroleum ether extract (50, 100 and 200 mg/kg, p.o.) administered for 14 successive days to mice significantly decreased the immobility periods in both

TST and FST, indicating significant antidepressant-like activity. Among three doses, the dose of 50 mg/kg of petroleum ether extract decreased the immobility period to the greatest extent, thus showed most potent antidepressant-like action. Imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.) administered for 14 successive days to mice significantly decreased the immobility periods in both TST and FST as compared to control, thus showed significant antidepressant-like action (Tables 1 and 2).

Effect of combination of Petroleum ether extract with sulpiride, baclofen, prazosin and *p*-CPA on immobility period in TST:

Sulpiride (50 mg/kg, i.p.), baclofen (10 mg/kg, i.p.) prazosin (62.5 µg/kg, i.p.) and *p*-CPA (100 mg/kg, i.p.) alone significantly increased the immobility period as compared to control group. Pretreatment of animals with sulpiride or baclofen or prazosin or *p*-CPA significantly reversed the decrease in immobility time elicited by petroleum ether extract at the dose 50 mg/kg (Table 3).

Effect of petroleum ether extract on brain monoamine oxidase (MAO) activities:

Petroleum ether extract (50 mg/kg) administered for 14 consecutive days to mice, significantly reduced the brain MAO-A and MAO-B levels as compared to

the respective vehicle treated groups. The efficacy of petroleum ether extract, was found to be comparable to imipramine (Figs. 1 and 2).

Effect on locomotor activity:

Petroleum ether extract (50 mg/kg, p.o.) administered for 14 successive days did not show any significant change in the locomotor function of mice (642.8 ± 84.5) as compared to the vehicle treated group (737.3 ± 50.1).

DISCUSSION

In the present study, petroleum ether extract (50, 100 and 200 mg/kg, p.o.) administered for 14 successive days to mice produced significant antidepressant-like effect in TST as well as in FST. The efficacy of the extract was found to be comparable to imipramine (15 mg/kg, p.o.) and sertraline (20 mg/kg, p.o.). FST and TST are two commonly used behavioral despair models of depression. These models are widely employed in rodents to predict antidepressant potential by decrease of immobility period produced by several different classes of antidepressant drugs³²⁻³³. Petroleum ether extract at the dose of 50 mg/kg, p.o. (most effective dose) did not show any significant change in locomotor functions of mice as compared to control, so it did not produce any motor effects. It confirmed the assumption that the antidepressant-like effect of the extract was specific and not the false positive. The precise mechanisms by which petroleum ether extract

TABLE 1: EFFECT OF *TINOSPORA CORDIFOLIA* ON IMMOBILITY PERIOD OF MICE USING TAIL SUSPENSION TEST

Group No.	Treatment for 14 days p.o.	Dose (kg-1)	Immobility Period (s)
1	Vehicle	10 ml	166.5±7.9
2	Imipramine	15 mg	112.8±3.9*
3	Sertraline	20 mg	79.8±6.4*
4	Petroleum ether extract	50 mg	107.3±6.3*
5	Petroleum ether extract	100 mg	112.2±6.6*
6	Petroleum ether extract	200 mg	121.3±4.6*

n=6 in each group; Values are in mean±SEM. Data was analyzed by one-way ANOVA followed by Dunnett's t-test. F(5,30)= 21.45; P< 0.05, *P< 0.05 when compared with vehicle treated group.

TABLE 2: EFFECT OF *TINOSPORA CORDIFOLIA* ON IMMOBILITY PERIOD OF MICE USING FORCED SWIM TEST

Group No.	Treatment for 14 days p.o.	Dose (kg-1)	Immobility Period (s)
7	Vehicle	10 ml	158.2±5.1
8	Imipramine	15 mg	109.8±7.7*
9	Sertraline	20 mg	106.6±4.9*
10	Petroleum ether extract	50 mg	82.3±5.5*
11	Petroleum ether extract	100 mg	95.5±8.4*
12	Petroleum ether extract	200 mg	97.0±7.6*

n=6 in each group; Values are in mean±SEM. Data was analyzed by one-way ANOVA followed by Dunnett's t-test. F(5,30)= 15.51; P< 0.05, *P< 0.05 when compared with vehicle treated group.

TABLE 3: EFFECTS OF SULPIRIDE, BACLOFEN, PRAZOSIN AND *p*-CPA ON ANTIDEPRESSANT-LIKE ACTIVITY OF *TINOSPORA CORDIFOLIA* IN TAIL SUSPENSION TEST

Group No.	Treatment for 14 days p.o.	Dose (kg-1)	Immobility Period (s)
1	Vehicle	10 ml	166.5±7.9
4	Petroleum ether extract	50 mg	107.3±6.3
13	Vehicle + Sulpiride	10 ml+50 mg	201.2±9.2*
14	Petroleum ether extract + Sulpiride	50 mg+50 mg	198.3±11.9#
15	Vehicle + Baclofen	10 ml+10 mg	231.8±7.2*
16	Petroleum ether extract + Baclofen	50 mg+10 mg	136.2±9.9#
17	Vehicle + Prazosin	10 ml+62.5 µg	203.2±5.9*
18	Petroleum ether extract + Prazosin	50 mg+62.5 µg	183.0±6.1#
19	Vehicle + <i>p</i> -CPA	10 ml+100 mg	212.8±4.9*
20	Petroleum ether extract + <i>p</i> -CPA	50 mg+100 mg	133.0±5.3#

n=6 in each group; Values are in mean±SEM. Data was analyzed by one-way ANOVA followed by Dunnett's t-test. F(4,25)= 10.989; P< 0.05 (for vehicle treated groups 1, 13, 15, 17 and 19). *P< 0.05 when compared with vehicle treated group (1). F(4,25)= 20.607; P< 0.05 (for petroleum ether extract treated groups 4, 14, 16, 18 and 20). #P< 0.05 when compared with petroleum ether extract treated group (4).




Fig. 1: Effect of petroleum ether extract of *T. cordifolia* on MAO-A activity
n=6 in each group; Values are in mean±SEM. Data was analyzed by one-way ANOVA followed by Dunnett's t-test. F (2,15)= 12.235; $P < 0.05$, * $P < 0.05$ when compared with vehicle treated group.




Fig. 2: Effect of petroleum ether extract of *T. cordifolia* on MAO-B activity
n=6 in each group; Values are in mean±SEM. Data was analyzed by one-way ANOVA followed by Dunnett's t-test. F(2,15)= 9.545; $P < 0.05$, * $P < 0.05$ when compared with vehicle treated group.

of *T. cordifolia* produced antidepressant-like effect are not completely understood. However according to our results, the antidepressant-like effect of the extract was significantly reversed by pretreatment of animals with prazosin (a α_1 -adrenoceptor antagonist), sulpiride (a selective dopamine D_2 -receptor antagonist), *p*-CPA (a serotonin synthesis inhibitor) and baclofen ($GABA_B$ agonist), when tested in TST. This suggested that the petroleum ether extract might produce antidepressant-like effect by interaction with α_1 -adrenoceptors, dopamine D_2 -receptors, serotonergic and $GABA_B$ receptors, hence increasing the levels of norepinephrine, dopamine and serotonin; and decreasing the levels of GABA in brains of mice. Levels of monoamines like norepinephrine, serotonin and dopamine are decreased in depression, so antidepressant drugs enhance the levels of these monoamines. $GABA_B$ receptor antagonism may serve as a basis for the generation of novel antidepressants⁴¹.

Moreover, petroleum ether extract also reduced the mouse whole brain MAO-A and MAO-B activities as compared to control, so it indicated that this extract inhibited the metabolism of monoamines, particularly serotonin and noradrenaline. Monoamine oxidase (MAO) regulates the metabolic degradation of catecholamines, serotonin and other endogenous amines in CNS. Inhibition of this enzyme causes a reduction in metabolism and subsequent increase in the concentration of biogenic amines. MAO-A preferentially metabolize adrenaline, nor-

adrenaline and serotonin. MAO-B metabolizes phenylethylamines. Dopamine is metabolized by both MAO-A and MAO-B⁴².

Thus, petroleum ether extract of *T. cordifolia* showed antidepressant-like activity probably by inhibiting MAO-A and MAO-B, thus increasing the levels of monoamines like noradrenaline, serotonin, and dopamine; and decreasing the levels of GABA. This was also supported by the earlier study where petroleum ether extract of *T. cordifolia* showed anti-stress activity⁴. According to results of phytochemical screening and literature, the antidepressant-like action of petroleum ether extract might be due to the presence of berberine (alkaloid), since the latter compound has been reported to have antidepressant-like activity⁴³, however the role of other constituents present in petroleum ether extract towards antidepressant-like activity needs to be explored. Therefore, *T. cordifolia* extract may have potential therapeutic value for the management of depressive disorders.

REFERENCES

- Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, *et al.* Differentiating antidepressants of the future: Efficacy and safety. *Pharmacol Therap* 2007;113:134-53.
- Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. *Hypericum perforatum* versus fluoxetine in the treatment of mild to moderate depression. *Adv Ther* 2002;19:43-53.
- Sarma DN, Khosa RL, Chansauria JP, Ray AK. Effect of *Tinospora cordifolia* on brain neurotransmitters in stressed rats. *Fitoterapia* 1995;67:421-2.

4. Patil M, Patki P, Kamath HV, Patwardhan B. Antistress activity of *Tinospora cordifolia* (Willd) Miers. *Indian Drugs* 1997;34:211-5.
5. Agarwal VS. *Drug Plants of India*. 1st ed. Vol. 2. Ludhiana: Kalyani Publishers; 1997. p. 688.
6. *Indian Herbal Pharmacopoeia*. Mumbai: Regional Research Laboratory, Jammu Tawi and Indian Drug Manufacturer's Association, Vol 1. 1998. p. 156-64.
7. Bhavamishra. *Bhavaprakasha Nigantu*. Varansai: Chaukhamba Bharti Academy, 1998. p. 270.
8. Agarwal A, Malini S, Bairy KL, Rao MS. Effect of *Tinospora cordifolia* on learning and memory in normal and memory deficit rats. *Indian J Pharmacol* 2002;34:339-49.
9. Singh RP, Banerjee S, Kumar PV, Raveesha KA, Rao AR. *Tinospora cordifolia* induces enzymes of carcinogen/drug metabolism and antioxidant system, and inhibits lipid peroxidation in mice. *Phytomed* 2006;13:74-84.
10. Rao PR, Kumar VK, Viswanath RK, Subbaraju GV. Cardioprotective activity of alcoholic extract of *Tinospora cordifolia* in ischemia-reperfusion induced myocardial infarction in rats. *Bio Pharm Bull* 2005;28:2319-22.
11. Mainzen S, Prince P, Menon VP, Gunasekaran G. Hypolipidaemic action of *Tinospora cordifolia* roots in alloxan diabetic rats. *J Ethnopharmacol* 1999;64:53-7.
12. Mainzen S, Prince P, Menon VP. Hypoglycaemic and hypolipidaemic action of alcohol extract of *Tinospora cordifolia* roots in chemical induced diabetes in rats. *Phytother Res* 2003;17:410-3.
13. Sarma DN, Khosa RL, Chansauria JP, Sahai M. Antiulcer activity of *Tinospora cordifolia* Miers and *Centella asiatica* Linn. extracts. *Phytother Res* 1995;9:589.
14. Bishayi B, Roychowdhury S, Ghosh S, Sengupta M. Hepatoprotective and immunomodulatory properties of *Tinospora cordifolia* in CCl₄ intoxicated mature albino rats. *J Toxicol Sci* 2002;27:139-46.
15. Gupta RS, Sharma A. Antifertility effect of *Tinospora cordifolia* (Willd.) stem extracts in male rats. *Indian J Exp Biol* 2003;41:885-9.
16. Faheem A, Ali M, Shokat RM. Anti-inflammatory activity and the standardization of *Tinospora cordifolia* stem bark. *Traditional system of medicine*. New Delhi: Narosa Publishing House; 2006. p. 414-7.
17. Badar VA, Thawani VR, Wakode PT, Shrivastava MP, Gharpure KJ, Hingorani LL, et al. Efficacy of *Tinospora cordifolia* in allergic rhinitis. *J Ethnopharmacol* 2005;96:445-9.
18. Manjrekar PN, Jolly CI, Narayanan S. Comparative studies of the immunomodulatory activity of *Tinospora cordifolia* and *Tinospora sinensis*. *Fitoterapia* 2000;71:254-7.
19. Jagetia GC, Rao SK. Evaluation of the antineoplastic activity of guduchi (*Tinospora cordifolia*) in Ehrlich ascites carcinoma bearing mice. *Biol Pharm Bull* 2006;29:460-6.
20. Goel HC, Prasad J, Singh S, Sagar RK, Agrawal PK, Bala M, et al. Radioprotective potential of an herbal extract of *Tinospora cordifolia*. *J Radiat Res (Tokyo)* 2004;45:61-8.
21. Pachaly P, Schneider C. Alkaloids from *Tinospora cordifolia* Miers. *Arch Pharm (Weinheim Ger)* 1981;314:251-6.
22. Bisset NG, Nwaiwu J. Quaternary alkaloids of *Tinospora* species. *Planta Medica* 1983;48:275-9.
23. Ghosal S, Vishwakarma RA. Tinocordiside: A new rearranged cadinane sesquiterpene glycoside from *Tinospora cordifolia*. *J Nat Prod* 1997;60:839-41.
24. Wazir V, Maurya R, Kapil RS. Cordioside: A clerodane furano diterpene glucoside from *Tinospora cordifolia*. *Phytochem* 1995;38:447-9.
25. Maurya R, Wazir V, Tyagi A, Kapil RS. Cordifoliosides A and B, two new phenylpropene disaccharides from *Tinospora cordifolia* possessing immunostimulant activity. *Nat Prod Lett* 1996;8:7-10.
26. Gangan VD, Pradhan P, Sipahimalani AT, Banerji A. Cordifoliosides A, B, C: Norditerpene furan glycosides from *Tinospora cordifolia*. *Phytochem* 1994;37:781-6.
27. Gangan VD, Pradhan P, Sipahimalani AT, Banerji A. Norditerpene furan glycosides from *Tinospora cordifolia*. *Phytochem* 1995;39:1139-42.
28. Pradhan P, Gangan VD, Sipahimalani AT, Banerji A. Two phytoecdysones from *Tinospora cordifolia*: Structural assignments by 2D NMR spectroscopy. *Indian J Chem Sec B* 1997;36:958-62.
29. Maurya R, Handa SS. Tinocordifolin, a sesquiterpene from *Tinospora cordifolia*. *Phytochem* 1998;49:1343-6.
30. Kokate CK. *Pharmacognosy*. 17th ed. Pune: Nirali Prakashan; 2001. p. 106-7.
31. Dhingra D, Sharma A. Antidepressant-like activity of *Glycyrrhiza glabra* L. in mouse models of immobility tests. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30:449-54.
32. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening antidepressants in mice. *Psychopharmacol (Berl)* 1985;85:367-70.
33. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. *Arch Int Pharmacodyn* 1977;229:327-36.
34. Abel EL, Bilitzke PJ. A possible alarm substance in the forced swimming test. *Physiol Behav* 1990;48:233-9.
35. Rodrigues AL, da Silva GL, Mateussi AS, Fernandes ES, Miguel OG, Yunes RA, et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extracts of *Siphocampylus verticillatus*. *Life Sci* 2002;70:1347-58.
36. Schurr A, Livne A. Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components. *Biochem Pharmacol* 1976;25:1201-3.
37. Pan Y, Kong L, Xia X, Zhang W, Xia W, Jiang F. Antidepressant-like effect of icariin and its possible mechanism in mice. *Pharmacol Biochem Behav* 2005;82:686-94.
38. Charles M, McEwan J. Metabolism of amino acids and amines. Monoamine oxidase (human serum/plasma and rabbit serum). In: Taboor H, Taboor CW, editors. *Methods in Enzymology*. New York and London: Academic Press, XVIII; 1971. p. 686-98.
39. Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of *Curcuma longa* in mice. *J Ethnopharmacol* 2002;83:161-5.
40. Lowry OH, Rosebrough NJ, Farr AL, Randall R. Protein measurement with folin phenol reagent. *J Biol Chem* 1951;193:265-75.
41. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA (B) receptors in the modulation of anxiety and antidepressant-like behavior. *Neuropsychopharmacol* 2004;29:1050-62.
42. Krishnan KR. Monoamine oxidase inhibitors. In: Schatzberg AF, Nemeroff CB, editors. *Textbook of Psychopharmacology*. 2nd ed. Washington DC: American Psychiatric Press; 1998. p. 239-49.
43. Kulkarni SK, Dhir A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. *Eur J Pharmacol* 2007;569:77-83.

Accepted 10 December 2008

Revised 5 December 2008

Received 16 April 2008

Indian J. Pharm. Sci., 2008, 70 (6): 761-767